Search
for
Sort by
Research 361–390 of 777
- AIRE Deficiency Leads to the Development of Alopecia Areata‒Like Lesions in Mice
- The X Factor in Immunity: Sex Differences Shaped by the X Chromosome
- Understanding the Intricate Pathophysiology of Psoriasis and Related Skin Disorders
- Advances in the treatment of autosomal recessive congenital ichthyosis, a look towards the repositioning of drugs
- Hair Growth Effect of DN106212 in C57BL/6 Mouse and Its Network Pharmacological Mechanism of Action
- Hair
- Assessing a measure for Quality of Life in patients with severe Alopecia Areata: a multicentric Italian study
- Inflammatory bowel disease: pathogenesis, diagnosis and current therapeutic approach
- Improvement in Patient‐Reported Emotional Symptoms and Activity Limitations due to Hair Loss in Patients With Alopecia Areata Treated With Ritlecitinib: Additional Analyses From ALLEGRO ‐2b/3
- Role of bulge epidermal stem cells and TSLP signaling in psoriasis
- Research Progress in Chronic Autoimmune Urticaria
- Update From Dermatology Nurses’ Association Convention 2025
- Association of JAK 1 and JAK 2 gene polymorphism with alopecia areata risk: a case–control genetic study
- UHPLC-Q-Orbitrap HRMS-based Metabolomics and In Silico Studies on 5-α-Reductase, JAK1, JAK2, and JAK3 of <i>Albizia saponaria</i> L.: Application to Alopecia
- INTERFERONS IN DERMATOLOGY
- Pathophysiology of Alopecia Areata in the Pediatric Patient
- Inflammatory auxo-action in the stem cell division theory of cancer
- Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata
- 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)
- JAK1 gain-of-function variant causes alopecia areata, atopic dermatitis, and autoimmune thyroid disease
- Progressive alopecia areata during TNF-α inhibition with intralesional corticosteroid failure and subsequent improvement following JAK1 inhibition
- CS12192 Reverses Alopecia Areata by Selectively Targeting JAK3/JAK1/TBK1.
- Short-term Efficacy of Tofacitinib, a JAK Inhibitor, in IFIH1-related Aicardi-Goutières Syndrome
- Efficacy of JAK 1/2 inhibition in the treatment of diffuse non-scarring alopecia due to systemic lupus erythematosus
- JAK kinase pathway inhibitor drugs in patients with moderate-to-severe alopecia: a real-world experience
- 69 Risk-benefit appraisal of systemic JAK inhibitors for alopecia areata: a comprehensive meta-analysis assessing safety and adverse effects
- Selective JAK 1 inhibition with upadacitinib as a potential treatment for coexistent severe atopic dermatitis and alopecia areata
- Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients
- Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata
- Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis